Press Releases
10.12.2007
- Study approval expected in first quarter of 2008
- Clinical test planned for various cancer indications
- Important 2007 target achieved by submitting this application
14.11.2007
- Revenue and earnings in line with planning
- Key advances reached in product pipeline
- Financial resources remain solid
04.06.2007
At its annual general meeting of June 1, 2007, the Berlin-based biotech company MOLOGEN AG has announced far reaching strategic decisions.
08.01.2007
The Berlin-based biotechnology company MOLOGEN AG announced today that it succeeded to upscale the production of its dSLIM® molecule significantly. The production volume has been increased by a factor of 25 to gram scale. At the same...
05.12.2006
SALVATOR Asset Management crosses 5-percent threshold
18.10.2006
The Berlin based Biotech company MOLOGEN announced today, that the basic patent for MIDGE®-TH1 technology has become legally binding in Europe.
3 Questions to Dr. Söhngen
Dr. Mariola Söhngen CEO MOLOGEN AG
Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50
Related Links